Search

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

63.15 1.32

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

60.96

Max

62.73

Põhinäitajad

By Trading Economics

Sissetulek

-8.4M

-111M

Aktsiakasum

-1.11

Töötajad

358

EBITDA

420K

-111M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+25.08% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

2. nov 2026

Turustatistika

By TradingEconomics

Turukapital

190M

6.2B

Eelmine avamishind

61.83

Eelmine sulgemishind

63.15

Uudiste sentiment

By Acuity

60%

40%

287 / 340 Pingereas Healthcare

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. aug 2026, 23:01 UTC

Xenon Pharmaceuticals Inc. is trading higher in after-market hours, despite no specific news to explain the move. The stock remains below its 20-day moving average.

15. aug 2026, 00:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, though no specific news was identified to explain the movement.

14. aug 2026, 23:01 UTC

Xenon Pharmaceuticals shares are higher in after-market hours, reflecting a modest gain since Friday's close. The stock remains below its 20-day moving average.

13. aug 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are declining, trading below their 20-day moving average amid broader market support, despite rising initial jobless claims.

12. aug 2026, 22:51 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, reflecting notable volatility and fluctuations since Wednesday's close within the one-month trading range.

11. aug 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and subdued trading activity.

10. aug 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite earlier pulling back from a session high. No specific news was identified for the movement.

7. aug 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares are lower as RBC cuts the price target to $81.00 and the company reports a larger-than-expected Q2 loss of $110.7 million.

6. aug 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. shares are lower today, retracing earlier gains. The stock is trading near the lower end of its one-month range.

5. aug 2026, 23:41 UTC

Xenon Pharmaceuticals Inc. shares are higher in after-market hours amid notable volatility, though no specific news was identified to explain the movement.

4. aug 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are trading lower during after-market hours, breaking a recent trend of higher daily closes since Tuesday.

3. aug 2026, 19:46 UTC

News

Xenon Pharmaceuticals announced equity inducement grants totaling 32,758 share options and 19,013 RSUs. Shares are lower during Monday's session, near the one-month range's low.

31. juuli 2026, 23:01 UTC

News

Xenon Pharmaceuticals shares are lower in after-market hours following the announcement of inducement grants for eleven new non-officer employees.

30. juuli 2026, 13:36 UTC

Xenon Pharmaceuticals Inc shares are higher in pre-market trading, reflecting a broader market recovery despite rising treasury yields and geopolitical tensions.

29. juuli 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are little changed after-market, continuing a trend of three consecutive lower daily finishes amid a broader decline in U.S. equities.

28. juuli 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are lower today, pulling back from earlier gains amid notable volatility and no specific news to explain the movement.

27. juuli 2026, 16:06 UTC

Xenon Pharmaceuticals Inc shares are lower today amid a broader market decline linked to falling crude oil prices and eased geopolitical tensions.

24. juuli 2026, 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting positive momentum since Friday's close, despite no specific news identified.

23. juuli 2026, 23:51 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours, continuing a downward trend with no specific news identified to explain the decline.

22. juuli 2026, 23:11 UTC

Xenon Pharmaceuticals Inc shares declined in after-market trading amid broader market volatility, influenced by geopolitical tensions and rising crude oil prices.

21. juuli 2026, 19:36 UTC

Xenon Pharmaceuticals shares are higher, supported by overall market strength and advances in biotechnology stocks, despite no specific company news identified.

20. juuli 2026, 22:02 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, following notable volatility and no specific news identified. The stock remains above its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

25.08% tõus

12 kuu keskmine prognoos

Keskmine 78 USD  25.08%

Kõrge 90 USD

Madal 63 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

12

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

287 / 340 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat